Dendrimers for enhanced drug solubilization

Nanomedicine

Volumn 3, Issue 5, 2008, Pages 679-702

  Svenson, Sonke ^a   Chauhan, Abhay S ^b  

^a Drug Delivery Solutions LLC   (United States)

^b Dendritic NanoTechnologies Inc   (United States)

Author keywords

Anti Inflammatory drugs; Anticancer drugs; Antimicrobial drugs; Bioavailability; Combination therapy; Dendrimers; Drug solubility; PEHAM; Poly(amidoamine) PAMAM; Poly(propylene imine) PPI

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ARTEMETHER PLUS BENFLUMETOL; ARTHROTEC; CAMPTOTHECIN; CURCUMIN; DENDRIMER; DICLOFENAC; DICLON; DIFENE; DIFLUNISAL; DOXORUBICIN; DRUG CARRIER; EPOSIN; ETOPHOS; ETOPOSIDE; EXCIPIENT; FLUOROURACIL; IRINOTECAN; LIPOSOME; MACROGOL; MEFENAMIC ACID; METHOTREXATE; MODIFENAC; NICLOSAMIDE; NIFEDICAL; NIFEDIPINE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PENNSAID; POLYAMIDOAMINE; POLYCAPROLACTONE; POLYMER; QUINOLONE DERIVATIVE; SULFAMETHOXAZOLE; TOPOTECAN; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLTEROL; ANTIVIRUS AGENT; BIOMATERIAL; PAMAM STARBURST; POLYAMINE;

ABDOMINAL PAIN; ANEMIA; ANOREXIA; ANTIINFLAMMATORY ACTIVITY; ANTIMICROBIAL ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE MARROW SUPPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG INDUSTRY; DRUG SOLUBILITY; DRUG STRUCTURE; DYSPNEA; EXHAUSTION; FEVER; GASTROINTESTINAL SYMPTOM; HAIR DISEASE; HEART ARRHYTHMIA; HUMAN; INJECTION SITE PAIN; INJECTION SITE SWELLING; NAUSEA; NAUSEA AND VOMITING; NONHUMAN; PRIORITY JOURNAL; REVIEW; SKIN BRUISING; SKIN TINGLING; TASTE DISORDER; THORAX PAIN; VOMITING; CHEMICAL MODEL; CHEMISTRY; HYDROLYSIS; METHODOLOGY; MICELLE; PHARMACEUTICS; SOLUBILITY;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; ANTIVIRAL AGENTS; BIOCOMPATIBLE MATERIALS; DENDRIMERS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; HYDROLYSIS; MICELLES; MODELS, CHEMICAL; POLYAMINES; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 55949114221     PISSN: 17435889     EISSN: None     Source Type: Journal    
DOI: 10.2217/17435889.3.5.679     Document Type: Review

References (74)

1. Svenson S: Carrier-Based Drug Delivery. ACS Symposium Series. American Chemical Society, Washington, DC, USA (2004).
2. Svenson S: Polymeric Drug Delivery I - Particulate Drug Carriers. ACS Symposium Series. American Chemical Society Washington, DC, USA (2006).
3. Svenson S: Dendrimers. In: Kirk-Othmer Encyclopedia of Chemical Technology (5th Edition). John Wiley & Sons, Inc., Hoboken, NJ, USA 786-812 (2007).
4. Svenson S, Tomalia DA: Dendrimers in biomedical applications: reflections on the field. Adv. Drug Deliv. Rev. 57, 2106-2129 (2005).
5. Svenson S, Tomalia DA: Dendrimers as nanoparticulate drug carriers. In: Nanoparticulates as Drug Carriers. Torchilin VP (Ed.), Imperial College Press, London, UK 277-299 (2006).
6. Gillies ER, Fréchet JMJ: Dendrimers and dendritic polymers in drug delivery. Drug Discov. Today 10, 35-42 (2005).
7. Tomalia DA: Birth of a new macromolecular architecture: dendrimers as quantized building blocks for nanoscale synthetic polymer chemistry. Prog. Polym. Sci. 30, 294-324 (2005).
8. Gupta U, Agashe HB, Asthana A, Jain NK: Dendrimers: novel polymeric nanoarchitectures for solubility enhancement. Biomacromolecules 7, 649-658 (2006).
9. Cheng Y, Wang J, Rao T, He X, Xu T: Pharmaceutical applications of dendrimers: promising nanocarriers for drug delivery. Front. Biosci. 13, 1447-1471 (2008).
10. Li Y, Cheng Y, Xu T: Design, synthesis and potent pharmaceutical applications of glycodendrimers. Curr. Drug Discov. Technol. 4, 246-254 (2007).
11. Cheng Y, Xu Z, Ma M, Xu T: Dendrimers as drug carriers: applications in different routes of drug administration. J. Pharm. Sci. 97, 123-143 (2008).
12. D'Emanuele A, Attwood D: Dendrimer-drug interactions. Adv. Drug Deliv. Rev. 57, 2147-2162 (2005).
13. Hatefl A, Amsden B: Camptothecin delivery methods. Pharm. Res. 19, 1389-1399 (2002).
14. Morgan MT, Nakanishi Y, Kroll DJ et al.: Dendrimer-encapsulated camptothecins: increased solubility, cellular uptake, and cellular retention afford enhanced anticancer activity in vitro. Cancer Res. 66, 11913-11921 (2006).
15. Markatou E, Gionis V, Chryssikos GD, Hatziantoniou S, Georgopoulos A, Demetzos, C: Molecular interactions between dimethoxycurcumin and PAMAM dendrimer carriers. Int. J. Pharm. 339(1-2), 231-236 (2007).
16. Kojima C, Kono K, Maruyama K, Takagishi T: Synthesis of polyamidoamine dendrimers having poly(ethylene glycol) grafts and their ability to encapsulate anticancer drugs. Bioconjug. Chem. 11, 910-917 (2000).
17. Papagiannaros A, Dimas K, Papaioannou GT, Demetzos C: Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines. Int. J. Pharm. 302, 29-38 (2005).
18. Gillies ER, Fréchet JMJ: pH-responsive copolymer assemblies for controlled release of doxorubicin. Bioconjug. Chem. 16, 361-368 (2005).
19. Wang F, Bronich TK, Kabanov AV, Rauh RD, Roovers J: Synthesis and evaluation of a star amphiphilic block copolymer from poly(ε-caprolactone) and poly(ethylene glycol) as a potential drug delivery carrier. Bioconjug. Chem. 16, 397-405 (2005).
20. Bhadra D, Bhadra S, Jain S, Jain NK: A PEGylated dendritic nanoparticulate carrier of fluorouracil. Int. J. Pharm. 257, 111-124 (2003).
21. Pan GF, Lemmouchi Y, Akala EO, Bakari O: Studies on PEGylated and drug-loaded PAMAM dendrimers. J. Bioact. Compat. Mol. 20, 113-128 (2005).
22. Dhanikula RS, Hidgen P: Influence of molecular architecture of polyether-co-polyester dendrimers on the encapsulation and release of methotrexate. Biomaterials 28, 3140-3152 (2007).
23. Patri AK, Kukowska-Latallo JF, Baker JR: Targeted drug delivery with dendrimers: comparison of the release kinetics of covalently conjugated drug and noncovalent drug inclusion complex. Adv. Drug. Deliv. Rev. 57, 2203-2214 (2005).
24. Shuai X, Merdan T, Schaper AK, Xi F, Kissel T: Core-crosslinked polymeric micelles as paclitaxel carriers. Bioconjug. Chem. 15, 441-448 (2004).
25. Shim WS, Kim SW, Choi EK, Park HJ, Kim JS, Lee DS: Novel pH-sensitive block copolymer micelles for solvent free drug loading. Macromol. Biosci. 6, 179-186 (2006).
26. Lee H, Zeng F, Dunne M, Allen C: Methoxy poly(ethylene glycol)-block-poly (δ-valerolactone) copolymer micelles for formulation of hydrophobic drugs. Biomacromolecules 6, 3119-3128 (2005).
27. Yusa S, Fukuda K, Yamamoto T, Ishihara K, Morishima Y. Synthesis of well-defined amphiphilic block copolymers having phospholipids polymer sequences as a novel biocompatible polymer micelle reagent. Biomacromolecules 6, 663-670 (2005).
28. Ooya T, Lee J, Park K: Hydrotropic dendrimers of generations 4 and 5: synthesis, characterization and hydrotropic solubilization of paclitaxel. Bioconjug. Chem. 15, 1221-1229 (2004).
29. Namazi H, Adeli M: Dendrimers of citric acid and poly(ethylene glycol) as the new drug delivery agents. Biomaterials 26, 1175-1183 (2005).
30. Cheng YY, Man N, Xu TW et al.: Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers. J. Pharm. Sci. 96, 595-602 (2007).
31. Yiyun C, Tongwen X: Dendrimers as potential drug carriers. Part I. Solubilization of nonsteroidal anti-inflammatory drugs in the presence of polyamidoamine dendrimers. Eur. J. Med. Chem. 40, 1188-1192 (2005).
32. Kolhe P, Misra E, Kannan RM, Kannan S, Lieh-Lai M: Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers. Int. J. Pharm. 259, 143-160 (2003).
33. Kannan S, Kolhe P, Raykova V et al.: Dynamics of cellular entry and drug delivery by dendritic polymers into human lung epithelial carcinoma cells. J. Biomater. Sci. Polym. Ed. 15, 311-330 (2004).
34. Chauhan AS, Jain NK, Diwan PV, Khopade AJ: Solubility enhancement of indomethacin with poly (amidoamine) dendrimers and targeting to inflammatory regions of arthritic rats. J. Drug Target. 12, 575-583 (2004).
35. Chauhan AS, Sridevi S, Chalasani KB et al.: Dendrimer mediated transdermal delivery: enhanced bioavailabitity of indomethacin. J. Control. Release 90, 335-343 (2003).
36. Chandrasekar D, Sistla R, Ahmad FJ, Khar RK, Diwan PV: Folate coupled poly(ethylene glycol) conjugates of anionic poly(amidoamine) dendrimer for inflammatory tissue specific drug delivery. J. Biomed. Mater. Res. 82A, 92-103 (2007).
37. Cheng Y, Xu T, Fu R: Polyamidoamine dendrimers used as solubility enhancers of ketoprofen. Eur. J. Med. Chem. 40, 1390-1393 (2005).
38. Man N, Cheng Y, Xu T et al.: Dendrimers as potential drug carriers. Part II. Prolonged delivery of ketoprofen by in vitro and in vivo studies. Eur. J. Med. Chem. 41, 670-674 (2006).
39. Devarakonda B, Hill RA, de Villiers MM: The effect of PAMAM dendrimer generation size and surface functional group on the aqueous solubility of nifedipine. Int. J. Pharm. 284, 133-140 (2004).
40. Devarakonda B, Li N, de Villiers MM: Effect of polyamidoamine (PAMAM) dendrimers on the in vitro release of water-insoluble nifedipine from aqueous gels. AAPS PharmSciTech 6(3), 63 (2005).
41. Zhu C, Hard C, Lin C, Gitsov I: Novel materials for bioanalytical and biomedical applications: environmental response and binding/release capabilities of amphiphilic hydrogels with shape-persistent dendritic junctions. J. Polym. Sci. [A1] 43, 4017-4029 (2005).
42. Ma M, Cheng Y, Xu Z et al.: Evaluation of polyamidoamine (PAMAM) dendrimers as drug carriers of anti-bacterial drugs using sulfamethoxazole (SMZ) as a model drug. Eur. J. Med. Chem. 42, 93-98 (2007).
43. Cheng Y, Qu H, Ma M et al.: Polyamidoamine (PAMAM) dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro study. Eur. J. Med. Chem. 42, 1032-1038 (2007).
44. Bhadra D, Bhadra S, Jain NK: Pegylated lysine based copolymeric dendritic micelles for solubilization and delivery of artemether. J. Pharm. Pharmaceut. Sci. 8, 467-482 (2005).
45. Devarakonda B, Hill RA, Liebenberg W, Brits M, de Villiers MM: Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins. Int. J. Pharm. 304, 193-209 (2005).
46. Yang H, Morris JJ, Lopina ST. Polyethylene glycol-polyamidoamine dendritic micelle as solubility enhancer and the effect of the length of polyethylene glycol arms on the solubility of pyrene in water. J. Colloid Interface Sci. 273, 148-154 (2004).
47. Paleos CM, Tsiourvas D, Sideratou Z, Tziveleka L: Acid- and salt-triggered multifunctional poly(propylene imine) dendrimer as a prospective drug delivery system. Biomacromolecules 5, 524-529 (2004).
48. Cho SY, Allcock HR: Dendrimers derived from polyphosphazenepoly (propyleneimine) systems: encapsulation and triggered release of hydrophobic guest molecules. Macromolecules 40, 3115-3121 (2007).
49. Beezer AE, King ASH, Martin IK, Mitchel JC, Twyman LJ, Wain CF: Dendrimers as potential drug carriers; encapsulation of acidic hydrophobes within water soluble PAMAM derivatives. Tetrahedron 59, 3873-3880 (2003).
50. Fernandez L, Gonzalez M, Cerecetto H, Santo M, Silber JJ: Solubilization and release properties of dendrimers: evaluation as prospective drug delivery systems. Supramol. Chem. 18, 633-643 (2006).
51. Dufès C, Keith WN, Bilsland A, Proutski I, Uchegbu IF, Schätzlein AG: Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors. Cancer Res. 65, 8079-8084 (2005).
52. Shaunak S, Thomas S, Gianasi E et al.: Polyvalent dendrimer glucosamine conjugates prevent scar tissue formation. Nat. Biotechnol. 22, 977-984 (2004).
53. Chen CZ, van Dyk T, Dhurjati P, La Rossa R, Cooper SL: Quarternary ammonium functionalized dendrimers as effective antimicrobials: structure-activity studies. Biomacromalecules 1, 473-480 (2000).
54. Chen CZ, Cooper SL: Interactions between dendrimer biocides and bacterial membranes. Biomaterials 23, 3359-3368 (2002).
55. Calabretta MK, Kumar A, McDermott AM, Cai C: Antibacterial activities of poly(amidoamine) dendrimers terminated with amino and poly(ethylene glycol) groups. Biomacromolecules 8, 1807-1811 (2007).
56. Rajakumar P, Ganesan K, Jayavelu S, Murugesan K: Synthesis and antibacterial activity of dendritic architectures. Synthesis (Stuttg.) 3, 528-532 (2006).
57. Pini A, Giuliani A, Falciani C et al.: Antimicrobial activity of novel dendrimeric peptides obtained by phage display selection and rational modification. Antimicrob. Agents Chemother. 49, 2665-2672 (2005).
58. McCarthy TD, Karellas P, Henderson SA et al.: Dendrimers as drugs: discovery and prectinical and clinical development of dendrimer-based microbicides for HIV and STI prevention. Mol. Pharm. 2, 312-318 (2005).
59. Rojo J, Delgado R: Glycodendritic structures: promising new antiviral drugs. J. Antimicrob. Chemother. 54, 579-581 (2004).
60. Boas U, Heegaard PMH: Dendrimers in drug research. Chem. Soc. Rev. 33, 43-63 (2004).
61. Domanski DM, Klajnert B, Bryszewska M: Influence of PAMAM dendrimers on human red blood cells. Bioelectrochemistry 63, 189-191 (2004).
62. Ducan R, Izzo L: Dendrimer biocompatibility and toxicity. Adv Drug Deliv. Rev. 57, 2215-2237 (2005).
63. Duncan R: The dawning era of polymer therapeutics. Nat. Rev. Drug. Discov. 2, 347-359 (2003).
64. Chen HT, Neerman MF, Parrish AR, Simanek EE: Cytotoxicity, hemolysis, and acute in vivo toxicity of dendrimers based on melamine, candidate vehicles for drug delivery. J. Am. Chem. Soc. 126, 10044-10048 (2004).
65. Jevprasesphant R, Penny J, Jalal R, Attwood D, McKeown NB, D'Emanuele A: The influence of surface modification on the cytotoxicity of PAMAM dendrimers. Int. J. Pharm. 252, 263-266 (2003).
66. El-Sayed M, Ginski M, Rhodes C, Ghandehari H: Transepithelial transport of poly(amidoamine) dendrimers across Caco-2 cell monolayers. J. Control. Release 81, 355-365 (2002).
67. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T: In vitro cytotoxicity testing of polycations: influence of polymer structure on cell viability and hemolysis. Biomaterials 24, 1121-1131 (2003).
68. Malik N, Wiwattanapatapee R, Klopsch R et al.: Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of I-125-labefled poly(amidoamine) dendrimers in vivo. J. Control. Release 65, 133-148 (2000).
69. Zinselmeyer BH, Mackay SP, Schatzlein AG, Uchegbu IF: The lower-generation polypropylenimine dendrimers are effective gene-transfer agents. Pharm. Res. 19, 960-967 (2002).
70. Yoo H, Juliano RL: Enhanced delivery of antisense oligonucleotides with fluorophore-conjugated PAMAM dendrimers. Nucleic Acids Res. 28, 4225-4231 (2000).
71. Bourne N, Stanberry LR, Kern ER, Holan G, Matthews B, Bernsteih DI: Dendrimers, a new class of candidate topical microbicides with activity against Herpes simplex virus infection. Antimicrob. Agents Chemother. 44, 2471-2474 (2000).
72. Roberts JC, Bhalgat MK, Zera RT: Preliminary biological evaluation of poly(amidoamine) (PAMAM) starburst dendrimers. J. Biomed. Mater. Res. 30, 53-65 (1996).
73. Padilla De Jesús OL, Ihre HR, Gagne L, Fréchet JMJ, Szoka Jr, FC: Polyester dendritic systems for drug delivery applications: in vitro and in vivo evaluation. Bioconjug. Chem. 13, 453-461 (2002).
74. Kobayashi H, Kawamoto S, Saga T et al.: Positive effects of polyethylene glycol conjugation to generation-4 polyamidoamine dendrimers as macromolecular MR contrast agents. Magn. Reson. Med. 46, 781-788 (2001).